Lv7
3298 积分 2021-07-21 加入
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAFV600E-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study
2小时前
已完结
EML4-ALK variant-specific genetic interactions shape lung tumorigenesis
10天前
已完结
PRT3789 is a First-in-Human SMARCA2-Selective Degrader that Induces Synthetic Lethality in SMARCA4-Mutated Cancers
10天前
已完结
Phase 1b and Dose-Expansion Study of GSK3326595, a PRMT5 Inhibitor as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cancers
15天前
已完结
Phase 1b and Dose-Expansion Study of GSK3326595, a PRMT5 Inhibitor as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cancers
17天前
已关闭
Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer
18天前
已完结
Phase 1b and Dose-Expansion Study of GSK3326595, a PRMT5 Inhibitor as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cancers
18天前
已关闭
Current Controversies and Challenges in Non–Oncogene-Addicted Synchronous Oligometastatic Non–Small Cell Lung Cancer
18天前
已完结
MTAP expression by immunohistochemistry: a novel biomarker in non-small cell cancer of the lung
26天前
已完结
First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial
1个月前
已完结
皖公网安备34019202002308
